Siponimod (Mayzent) - A New Drug for Multiple Sclerosis

Date: May 6, 2019 Issue #:  1571Summary:  The FDA has approved siponimod (Mayzent– Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Siponimod i s the second S1P receptor modulator to be approved in the US; fingolimod(Gilenya), which is approved for oral treatment of relapsing forms of MS in patients≥10 years old, was the first. The purine antimetabolite cladribine(Mavenclad) was also recently approved for oral treatment of relapsing forms of MS and will be reviewed in a future issue.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Alemtuzumab Aubagio Avonex Cladribine dimethyl fumarate Fingolimod Gilenya Glatect Glatiramer acetate Glatopa interferod beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy sipo Source Type: research